Regenxbio Inc - Asset Resilience Ratio
Regenxbio Inc (RGNX) has an Asset Resilience Ratio of 39.56% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check RGNX strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2025)
This chart shows how Regenxbio Inc's Asset Resilience Ratio has changed over time. See debt-free asset ratio of Regenxbio Inc to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Regenxbio Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Regenxbio Inc (RGNX) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $135.26 Million | 39.56% |
| Total Liquid Assets | $135.26 Million | 39.56% |
Asset Resilience Insights
- Very High Liquidity: Regenxbio Inc maintains exceptional liquid asset reserves at 39.56% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Regenxbio Inc Industry Peers by Asset Resilience Ratio
Compare Regenxbio Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC |
Biotechnology | -55.36% |
|
Krystal Biotech Inc
NASDAQ:KRYS |
Biotechnology | 23.06% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
BB Biotech AG
SW:BION |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for Regenxbio Inc (2015–2025)
The table below shows the annual Asset Resilience Ratio data for Regenxbio Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 43.18% | $195.60 Million | $453.03 Million | +5.16pp |
| 2024-12-31 | 38.02% | $177.16 Million | $465.99 Million | -3.92pp |
| 2023-12-31 | 41.94% | $240.74 Million | $573.97 Million | +9.82pp |
| 2022-12-31 | 32.13% | $267.69 Million | $833.27 Million | +22.05pp |
| 2021-12-31 | 10.08% | $112.23 Million | $1.11 Billion | -9.31pp |
| 2020-12-31 | 19.39% | $137.31 Million | $708.16 Million | -26.14pp |
| 2019-12-31 | 45.53% | $226.70 Million | $497.91 Million | +0.62pp |
| 2018-12-31 | 44.91% | $244.20 Million | $543.81 Million | -12.54pp |
| 2017-12-31 | 57.44% | $114.12 Million | $198.68 Million | +19.98pp |
| 2016-12-31 | 37.46% | $64.71 Million | $172.73 Million | +10.35pp |
| 2015-12-31 | 27.11% | $60.02 Million | $221.38 Million | -- |
About Regenxbio Inc
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular … Read more